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Introduction: Cystic ﬁbrosis (CF) is the most common genetic disorder in Caucasians. Presentation of CF in non-Caucasians is less well studied.
Objective: This audit was undertaken to determine the phenotypic expression of the 3120+1GNA mutation in black and mixed race children in
South Africa.
Methods: A multi-centre retrospective chart review of clinical, laboratory and spirometry data of non-Caucasian CF patients in four CF centres in
South Africa was collected. Data was collected at diagnosis and after a ﬁve-year follow-up period. Ethical approval was granted for the study.
Results: A total of 30 participants were enrolled of whom 14 (47%) were homozygous and 16 (53%) heterozygous for the 3120+1GNA mutation.
The mean age of diagnosis was 13 months. Twenty-four (80%) patients had malnutrition (mean weight z-score −3.6) or failure to thrive (77%) at
presentation. Twenty (67%) presented with non-speciﬁc abdominal symptoms, whilst ﬁfteen (50%) had recurrent respiratory tract infections.
Pseudomonas aeruginosa was detected at a mean age of 21 months. The mean FEV1 was 73% predicted (95% CI 54.0–91.1) at study entry and
68% predicted (95% CI 49.74–87.06) at follow-up.
Conclusion: Failure to thrive and a diagnosis of protein energy malnutrition (kwashiorkor) are the common presenting features of CF in children with
the 3120+1GNA mutation. Meconium ileus is a rare presenting feature of CF in black and mixed race children with this deletion in South Africa.
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Cystic fibrosis (CF) is a one of the most common severe
autosomal recessive disorders in Caucasians. CF occurs as a
result of mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene found on the long arm
of chromosome 7 [1–3]. Over 1900 mutations have been⁎ Corresponding author at: Level D3 Bridge C, Steve Biko Academic Hospital,
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Caucasians [4]. In the South African Caucasian population,
p.F508del accounts for up to 81% of all CF alleles [5]. The
p.F508del mutation is less frequent in the South African
mixed-race (53%) and black African populations where it's
rarely detected.
The 3120+1GNA CFTR mutation was first reported in three
African-American CF patients by Macek et al., and has
subsequently been shown to account for 9–14% of African-
American CF mutations [6]. Analysis of the CFTR gene and
its expression in African-American CF patients has shown a
significantly different profile from that observed in Caucasianby Elsevier B.V. All rights reserved.
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presentation of black and white patients with CF have shown
some differences in clinical presentation and morbidity related
to CF. Differences include a higher incidence of malnutrition,
severe lung disease and a higher rate of meconium ileus in black
patients [7–9], with one case series describing the phenotype
associated with the 3120+1GNA mutation as presenting with
mild to moderate sinopulmonary symptoms [10].
In South Africa, the most common CF disease causing
mutation in black South Africans is the 3120+1GNA mutation,
which is detected in 46% of all CF alleles, with a carrier rate
of 1 in 90 [11]. With this carrier rate and the presence of other
mutations, over 1000 black African babies with CF are estimated
to be born each year in South Africa [9]. A study conducted
in Cape Town, revealed that the 3120+1GNA mutation was
the second most common mutation in the mixed race children,
after the p.F508del mutation [12].
Until recently, the spectrum of disease in the mixed race and
black African population has remained poorly understood.
Recognition of CF in an African context is difficult due to the
overwhelming burden and high prevalence of poverty-associated
conditions with similar presentations namely protein energy
malnutrition (PEM), human immunodeficiency virus infection
(HIV) and tuberculosis. Therefore, diagnosis of CF and insti-
tution of therapy may be delayed, impacting negatively on the
outcome.
We therefore undertook this study with the primary aim
being to assess the phenotypic expression of the 3120+1GNA
mutation in black and mixed race children with CF in South
Africa. A secondary objective was to assess the age of diagnosis
and the overall morbidity of children with the 3120+1GNA
mutation.Table 1
Baseline data of black and mixed race children with cystic fibrosis with a
3120+1GNA mutation.
Variable Frequency Percentage (%)
Gender (M/F) 16:14 53:47
Age diagnosis (months) 13
Ethnic group
Mixed race 10 33
Black African 20 67
Mutation
Homozygous 3120+1GNA 14 472. Patients and methods
2.1. Study population
A retrospective chart review of black and mixed race CF
patients at four CF centres was conducted, namely, the Paediatric
Cystic Fibrosis Clinics at Steve Biko Academic Hospital
(SBAH), Pretoria; the CharlotteMaxeke Johannesburg Academic
Hospital (CMJAH), Johannesburg; the Tygerberg Hospital
(TBH), Cape Town and the Red Cross War Memorial Children's
Hospital (RCWMCH), Cape Town. Subjects were included in
the study if there was laboratory confirmation of CF with the
presence of at least one copy of the 3120+GNA mutation by
molecular testing.Heterozygous 3120+GNA 16 53
Clinical presentation
Respiratory tract infection 15 50
Failure to thrive 24 80
PEM (kwashiorkor) 23 77
Abdominal symptoms 20 67
Other 9 30
Pancreatic insufficiency 29 97
PEM: protein energy malnutrition; abdominal symptoms: included meconium
ileus, rectal prolapse and chronic diarrhoea.2.2. Clinical investigations
The clinical data collected included: age at diagnosis,
weight, height, and body mass index (BMI) {World Health
Organization defined z-scores for weight, height and BMI}
[13]. All data was collected at diagnosis and after a five year
follow-up period.2.3. Laboratory investigations
The data collected included: screening sweat chloride con-
ductivity (Nanoduct™Neonatal Sweat Analysis System,Wescor,
Inc., South Logan, UT, USA) and faecal elastase (ELISA kit,
ScheBo® Pancreatic Elastase 1 Stool Test). Results of sputum
microbiology were collected. The colonisation status of the
airway pathogens identified was also noted. Colonisation was
defined as the persistence of a pathogen on two or more sputum
samples over a period of six months as defined in the Leeds
criteria for chronic infection [14].
Pulmonary function parameters for all subjects over the age
of six years were collected for forced expiratory flow in 1 s
(FEV1) and forced vital capacity (FVC) [ViasysSpiroPro Jaeger
Spirometer Cardinal Health, Hoechberg, Germany].
2.4. Ethical clearance
Ethic approval to access the patient records was obtained
from the Research Ethics Committees of the University of
Pretoria, Witwatersrand University and University of Cape
Town.
3. Results
A total of 30 patients of whom 20 (67%) were black
Africans were included in the study. There were 53% males. Of
the total number of subjects the patient distribution per site was:
47% (RCWMCH), 27% (SBAH), 20% (CMJAH) and 6%
(TBH). Fourteen (47%) of the participants were homozygous
for the 3120+GNA mutation, whilst sixteen (53%) were
heterozygous. The baseline characteristics of the participants
are summarised in Table 1. The mean age at diagnosis was
13.0 months (95% CI 6.5; 19.4). At presentation the subjects
were stunted and severely underweight with height and weight
z-scores of −2.6 (95% CI −3.9; −1.3) and −3.6 (95% CI −4.6;
−2.6), respectively (Table 2).
Table 2
Baseline clinical parameters of children with a 3120+1GNA cystic fibrosis at
diagnosis and follow-up.
Variable Presentation (mean; 95% CI) Follow-up (mean; 95% CI)
Age (months) 13.0 (6.6; 19.4) 69.2 (44.9; 93.5)
WAZ −3.6 (−4.6; −2.6) −1.2 (−2.5; 0.6)
HAZ −2.6 (−3.9; −1.3) −2.4 (−3.3; −1.6)
BMI 12.9 (11.9; 14.0) 14.7 (13.1; 16.3)
FEV1 72.5 (54.0; 91.1) 68.4 (49.7; 87.1)
HAZ: height for age z-score; WAZ: weight for age z-score; BMI: body mass
index; FEV1: forced expiratory flow in 1 s.
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insufficient at diagnosis. In twenty-three (77%) participants the
original diagnosis at presentation was protein energy malnu-
trition. Fifteen patients (50%) already had respiratory symptoms
at diagnosis. Pulmonary function tests were available in thirteen
subjects (43%) with a mean FEV1 of 72.5% predicted (95% CI
53.9; 91.1) at baseline. Staphylococcus aureus (40%) and
Pseudomonas aeruginosa (Pa) (60%) were the most common
colonising the airway. The mean age of the first identification
of S. aureus and Pa was 17.0 months and 21.0 months of age,
respectively. Gastrointestinal complications were identified at
presentation in 27% with liver cholestasis present in 10% of the
participants.
On 5 year follow-up, six (20%) of the participants had died
and there were twenty-three survivors (77%) (Table 3). Of the 6
patients who died, three demised from respiratory failure (two
were colonised with Pa and one with S. aureus), one each from
overwhelming sepsis, liver failure and hypovolemic shock from
gastroenteritis. In one patient outcome was unknown as the
patient was lost to follow-up.
On follow-up, there was improvement in all the growth
parameters (Table 2). Lung function decline in those with Pa
was more severe than in those without Pa; FEV1 decline of 15%
versus 4%, respectively, over the five year follow-up period.
One patient developed CF-related diabetes, and this patient was
a compound heterozygote with the 3120+1GNA/p.F508del
mutation.
The most common complications at follow-up were respira-
tory in nature (46%) with recurrent chest infections defined
as more than 4 exacerbations per year for the study period.Table 3
The follow-up of black and mixed-race children with cystic fibrosis.
Frequency Percentage (%)
Respiratory cultures
Pseudomonas aeruginosa 13 43
Staphylococcus aureus 13 43
Complications
Respiratory 13 46
Abdominal 8 27
Liver dysfunction 3 10
Poor growth 3 10
Outcome
Alive 23 77
Dead 6 20
Unknown 1 3Abdominal complications were the second most common (27%),
which included distal intestinal obstruction, meconium ileus
equivalent and rectal prolapse. Only 10% of the subjects de-
veloped liver cholestasis and had poor growth on follow-up.
4. Discussion
There is a wide range of phenotypic presentations in CF
with striking differences between black and white patients,
mostly being noted in gastrointestinal manifestations and
nutritional status [15]. Previous studies have suggested that
the 3120+1GNA mutation is a milder mutation with more
abdominal symptomatology, especially meconium ileus. This
mutation has been more commonly observed among black
patients, reflecting the lower prevalence of p.F508del in that
group [15]. In the current study, we have shown that the mean
age of diagnosis of the study population was over the age of
one year. In the majority of patients failure to thrive and protein
energy malnutrition were the most common presenting features.
Abdominal symptoms were a presenting feature in only a third
of the study population. Moreover, the acquisition of Pa col-
onisation was within the first two years of life. Almost all the
participants had pancreatic insufficiency at presentation.
There is a delay in the diagnosis of children with CF in
our population. This is in contra-diction to African-American
children where the mean age of diagnosis is eight months [8].
This can be attributed to the lack of awareness of CF (which is
believed to be rare in this population group), poor access to
medical care and missed diagnosis as malnutrition secondary to
conditions of poverty. The classic triad for a CF diagnosis is
recurrent or persistent respiratory symptoms, pancreatic insuffi-
ciency and poor weight gain [16]. A previous study of 181 CF
patients in South Africa showed that only 4.6% of patients
presented with all 3 features thus limiting its value in this context
[17]. This may account for the delay in diagnosis in the current
cohort. Another diagnosis limiting factor is that in order for CF
to be confirmed, identification of the CFTR gene mutations is
necessary, and in the current mutational analysis panel used in
South Africa, only 76% and 46% of mutations are detected in
the mixed race and black African CF, respectively [17]. Full
sequencing of the entire CFTR coding region is also unavailable
to the majority of South African patients due to cost restraints.
This implies that a significant number of patients are missed due
to inability to identify 2 disease-causing CFTR mutations [18].
Pulmonary function parameters, particularly FEV1 have been
shown to be a reliable outcome measure in most studies and are
used as a predictor of lung disease progression and mortality [19].
Vandenbranden et al. demonstrated that nutrition remained a
strong predictor for accelerated decline in FEV1 [20]. Morrow et
al. in a longitudinal 8 year follow-up of children in Cape Town,
demonstrated a 20% improvement in the median pulmonary
function scores over the follow-up period [21]. They ascribed
this to the improved multidisciplinary team approach in the man-
agement of CF patients. The current study revealed a decline
of FEV1 of between 3%/year in those with Pa compared to
0.8%/year in those not colonised with Pa. This decline is slightly
higher than that reported byMorrow et al., where the rate of FEV1
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3120+1GNA mutation may confer a more severe lung disease
when compared to a cohort of whom the majority largely had
the p.F508del mutation.
The strength of this study is that all possible children with the
3120+1GNA mutation in South Africa were included and should
serve as a study of the phenotypic presentation and longitudinal
follow-up of non-Caucasian children with the 3120+1GNA
mutation. The study has a number of limitations, one being the
small number of participants and limits generalisability. There
were also few participants who provided pulmonary function data.
In summary, failure to thrive and protein energy malnutrition
are the commonest presenting features of CF in black and mixed
race South African children with the 3120+1GNA mutation.
Increased awareness of CF in non-Caucasian African children is
therefore necessary. Clinicians should consider CF when in-
vestigating children who present with unexplained malnutrition,
where nutritional and social factors have been optimised and
growth still remains sub-optimal.
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